title: The new concepts on overcoming drug resistance in lung cancer.
abstract: Lung cancer is one of the most deadly diseases worldwide. The current first-line therapies include chemotherapy using epidermal growth factor receptor tyrosine kinase inhibitors and radiotherapies. With the current progress in identifying new molecular targets, acquired drug resistance stands as an obstacle for good prognosis. About half the patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor treatments develop resistance. Although extensive studies have been applied to elucidate the underlying mechanisms, evidence is far from enough to establish a well-defined picture to correct resistance. In the review, we will discuss four different currently developed strategies that have the potential to overcome drug resistance in lung cancer therapies and facilitate prolonged anticancer effects of the first-line therapies.
authors.affiliation: Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
authors.forename: Weisan
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
authors.forename: Ping
authors.initials: P
authors.lastname: Lei
authors.affiliation: Department of Hematology-Oncology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
authors.forename: Xifeng
authors.initials: X
authors.lastname: Dong
authors.affiliation: Qianfoshan Hospital, Shandong University, Jinan, People's Republic of China.
authors.forename: Cuiping
authors.initials: C
authors.lastname: Xu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
keywords: ALK receptors cancer stem cell; EGFR-TKI; biotherapy; chemotherapy; molecular biology; pharmacology; target therapy